Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    April 2017
  1. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Text format     Abstract available



  2. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed     Text format    


  3. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Text format     Abstract available


    March 2017

  4. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  5. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Text format     Abstract available


    December 2016
  6. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Text format     Abstract available


  7. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Text format     Abstract available


    November 2016
  8. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Text format     Abstract available


  9. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


    October 2016
  10. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Text format     Abstract available


  11. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  12. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Text format     Abstract available


    September 2016
  13. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Text format     Abstract available


  14. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Text format     Abstract available


    August 2016
  15. LIN F, de Gooijer MC, Hanekamp D, Chandrasekaran G, et al
    PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1276.2016.
    PubMed     Text format     Abstract available


  16. CALINESCU AA, Yadav VN, Carballo E, Kadiyala P, et al
    Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.2888.2015.
    PubMed     Text format     Abstract available


  17. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


  18. REINARTZ R, Wang S, Kebir S, Silver DJ, et al
    FUNCTIONAL SUBCLONE PROFILING FOR PREDICTION OF TREATMENT-INDUCED INTRA-TUMOR POPULATION SHIFTS AND DISCOVERY OF RATIONAL DRUG COMBINATIONS IN HUMAN GLIOBLASTOMA.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.2089.2015.
    PubMed     Text format     Abstract available


  19. LOWENSTEIN PR, Castro MG
    Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1477.2016.
    PubMed     Text format     Abstract available


    July 2016
  20. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available


    June 2016
  21. KIM JE, Patel MA, Mangraviti A, Kim ES, et al
    Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.1535.2015.
    PubMed     Text format     Abstract available


  22. KALININA J, Ahn J, Devi NS, Wang L, et al
    Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
    Clin Cancer Res. 2016 Jun 23. pii: clincanres.2965.2015.
    PubMed     Text format     Abstract available


  23. NIESSNER H, Schmitz J, Tabatabai G, Schmid A, et al
    PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.0064.2016.
    PubMed     Text format     Abstract available


  24. GENG F, Cheng X, Wu X, Yoo JY, et al
    Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.2973.2015.
    PubMed     Text format     Abstract available


    May 2016
  25. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  26. RAMPLING R, Peoples S, Mulholland PJ, James A, et al
    A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2016 May 25. pii: clincanres.0506.2016.
    PubMed     Text format     Abstract available


  27. OLOW A, Mueller S, Yang X, Hashizume R, et al
    BRAF status in personalizing treatment approaches for pediatric gliomas.
    Clin Cancer Res. 2016 May 23. pii: clincanres.1101.2015.
    PubMed     Text format     Abstract available


  28. XU R, Shimizu F, Hovinga K, Beal K, et al
    Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Clin Cancer Res. 2016 May 6. pii: clincanres.0048.2016.
    PubMed     Text format     Abstract available


  29. WICK W, Gorlia T, Bady P, Platten M, et al
    Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082).
    Clin Cancer Res. 2016 May 3. pii: clincanres.3153.2015.
    PubMed     Text format     Abstract available



  30. Correction: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
    Clin Cancer Res. 2016;22:2313.
    PubMed     Text format    


    April 2016
  31. TATEISHI K, Iafrate AJ, Ho Q, Curry WT, et al
    Myc-driven glycolysis is a therapeutic target in glioblastoma.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2274.2015.
    PubMed     Text format     Abstract available


    March 2016
  32. LUN X, Wells JC, Grinshtein N, King JC, et al
    Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of Glioblastoma.
    Clin Cancer Res. 2016 Mar 22. pii: clincanres.1798.2015.
    PubMed     Text format     Abstract available


  33. YAO Y, Ye H, Qi Z, Mo L, et al
    B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  34. PALANICHAMY K, Thirumoorthy K, Kanji S, Gordon N, et al
    Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2308.2015.
    PubMed     Text format     Abstract available


    February 2016
  35. CURRY WT, Gorrepati R, Piesche M, Sasada T, et al
    Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Anti-tumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Clin Cancer Res. 2016 Feb 12. pii: clincanres.2163.2015.
    PubMed     Text format     Abstract available


    December 2015
  36. KEBIR S, Fimmers R, Galldiks N, Schaefer N, et al
    Late Pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.1334.2015.
    PubMed     Text format     Abstract available


  37. MARTUSCELLO RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, et al
    A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.0916.2015.
    PubMed     Text format     Abstract available


    November 2015
  38. MA Y, Tang N, Thompson RC, Mobley B, et al
    InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma.
    Clin Cancer Res. 2015 Nov 11. pii: clincanres.1677.2015.
    PubMed     Text format     Abstract available


  39. ANDRONESI OC, Loebel F, Bogner W, Marjanska M, et al
    Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Clin Cancer Res. 2015 Nov 3. pii: clincanres.0656.2015.
    PubMed     Text format     Abstract available


    October 2015
  40. HUANG RY, Rahman R, Ballman KV, Felten S, et al
    The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.3040.2014.
    PubMed     Text format     Abstract available


  41. JACKSON CM, Kochel CM, Nirschl CJ, Durham NM, et al
    Systemic Tolerance Mediated by Melanoma Brain Tumors is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
    PubMed     Text format     Abstract available


  42. VERREAULT M, Schmitt C, Goldwirt L, Pelton K, et al
    Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.1015.2015.
    PubMed     Text format     Abstract available


  43. MAR N, Desjardins A, Vredenburgh JJ
    CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma-The Progress and the Limitations.
    Clin Cancer Res. 2015;21:4248-50.
    PubMed     Text format     Abstract available


    September 2015
  44. PHAM CD, Flores C, Yang C, Pinheiro EM, et al
    Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma.
    Clin Cancer Res. 2015 Sep 24. pii: clincanres.0713.2015.
    PubMed     Text format     Abstract available



  45. Correction: PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas.
    Clin Cancer Res. 2015;21:4243.
    PubMed     Text format    


    July 2015
  46. SINGH SK, Venugopal C, Hallett R, Vora P, et al
    Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.3147.2014.
    PubMed     Text format     Abstract available


    June 2015
  47. KIM SJ, Lee HJ, Kim SW, Choi HJ, et al
    Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.3195.2014.
    PubMed     Text format     Abstract available


  48. HANNIFORD D, Zhong J, Koetz L, Gaziel-Sovran A, et al
    A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.2566.2014.
    PubMed     Text format     Abstract available


  49. BROWN CE, Badie B, Barish ME, Weng L, et al
    Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2015 Jun 9. pii: clincanres.0428.2015.
    PubMed     Text format     Abstract available


    May 2015
  50. SHI Y, Chen C, Yu S, Liu Q, et al
    miR-663 suppresses oncogenic function of CXCR4 in glioblastoma.
    Clin Cancer Res. 2015 May 28. pii: clincanres.2807.2014.
    PubMed     Text format     Abstract available


    March 2015
  51. KLUGER H, Zito CR, Barr M, Baine M, et al
    Characterization of PD-L1 Expression and Associated T cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Clin Cancer Res. 2015 Mar 18. pii: clincanres.3073.2014.
    PubMed     Text format     Abstract available


    February 2015
  52. CARVAJAL RD, Lawrence DP, Weber J, Gajewski TF, et al
    Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.1630.2014.
    PubMed     Text format     Abstract available


    January 2015
  53. HOFER S, Mengele K, Schmitt M, Pestalozzi B, et al
    Complement activation and rituximab distribution in CNS NHL--letter.
    Clin Cancer Res. 2015;21:490.
    PubMed     Text format    


  54. MORENO L, Marshall LV, Pearson AD, Morland B, et al
    A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
    Clin Cancer Res. 2015;21:267-73.
    PubMed     Text format     Abstract available


  55. MERINO DM, Shlien A, Villani A, Pienkowska M, et al
    Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups.
    Clin Cancer Res. 2015;21:184-92.
    PubMed     Text format     Abstract available


    May 2014
  56. CHEN G, Chakravarti N, Aardalen K, Lazar AJ, et al
    Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: